Peer-Reviewed Publication
ESMO Gastrointest Oncol2026;13(Pt B):100344.September 1, 2026Journal Article
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.
M Malla1, A Esmail2, A Tin3, M M Khayat3, L Bathla4, C Bridges3, C M Brewer3, J Ferguson3, J B Ortiz3, J Ensor3, K Magee3, J Yu5, A R He6, T Cannon7, A Winer7, G G King8, A Mahipal9, A Nagarajan10, J W Franses11, A Fungtammasan3, A Jurdi3, M C Liu3, S Kodali2, A A Connor2, R M Ghobrial2, R D Kim5, M Abdelrahim2
1University of Alabama at Birmingham, Birmingham, USA.
2Houston Methodist Neal Cancer Center, Houston, USA.
3Natera, Inc., Austin, USA.
4Texas Oncology, San Antonio, USA.
5H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
6Georgetown University Medical Center, Washington, DC, USA.
7Inova Schar Cancer Institute, Fairfax, USA.
8Fred Hutchinson Cancer Center, Seattle, USA.
9Seidman Cancer Center, Case Western Reserve University, Cleveland, USA.
10Cleveland Clinic Florida, Weston, USA.
11University of Chicago, Chicago, USA.
Abstract
BACKGROUND: Growing evidence supports the prognostic and predictive value of circulating tumor DNA (ctDNA) in gastrointestinal cancers. This study evaluated ctDNA as a prognostic biomarker for detecting molecular residual disease (MRD) and recurrence in patients with resected biliary tract cancer (BTC).
MATERIALS AND METHODS: We retrospectively analyzed real-world data from patients (N = 167) wit…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans